Scarica l'app Stockscreener
0.799
1.36%
-0.011
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DRRX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.81
Aprire:
$0.8
Volume 24 ore:
16,377
Relative Volume:
0.16
Capitalizzazione di mercato:
$24.80M
Reddito:
$8.59M
Utile/perdita netta:
$-17.07M
Rapporto P/E:
-1.3098
EPS:
-0.61
Flusso di cassa netto:
$-21.90M
1 W Prestazione:
+3.90%
1M Prestazione:
-5.08%
6M Prestazione:
-40.15%
1 anno Prestazione:
-9.21%
Intervallo 1D:
$0.77
$0.80
Intervallo di 1 settimana:
$0.7602
$0.83
Portata 52W:
$0.701
$1.88
Durect Corp Stock (DRRX) Company Profile
Nome
Durect Corp
Settore
Telefono
(408) 777-1417
Indirizzo
10240 BUBB ROAD, CUPERTINO, CA
Confronta DRRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DRRX
Durect Corp
|
0.799 | 24.80M | 8.59M | -17.07M | -21.90M | -0.61 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Durect Corp Stock (DRRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-10-30 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-12 | Iniziato | ROTH Capital | Buy |
| 2020-07-31 | Iniziato | Oppenheimer | Outperform |
| 2020-01-31 | Iniziato | B. Riley FBR | Buy |
| 2019-11-18 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-09-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-03-06 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2017-10-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2017-10-20 | Reiterato | Laidlaw | Buy |
| 2017-10-20 | Downgrade | Stifel | Buy → Hold |
| 2017-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2017-02-28 | Ripresa | H.C. Wainwright | Buy |
| 2016-04-25 | Iniziato | Rodman & Renshaw | Buy |
| 2015-05-01 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-05-01 | Reiterato | Stifel | Buy |
| 2013-03-25 | Iniziato | Stifel | Buy |
| 2012-11-01 | Downgrade | C.K. Cooper | Buy → Hold |
| 2012-08-17 | Iniziato | C.K. Cooper | Buy |
| 2009-06-23 | Iniziato | Caris & Company | Buy |
| 2009-03-26 | Iniziato | Wedbush Morgan | Hold |
Mostra tutto
Durect Corp Borsa (DRRX) Ultime notizie
DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com - Defense World
DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com - Defense World
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
StockNews.com Initiates Coverage on DURECT (NASDAQ:DRRX) - Defense World
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence - Stockhouse Publishing
Revolutionary Liver Disease Drug Cuts Death Risk by More Than Half in US Patients - StockTitan
DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Durect (DRRX) Upgraded to Strong Buy: Here's Why - Yahoo Finance
DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
Geode Capital Management LLC Has $429,000 Holdings in DURECT Co. (NASDAQ:DRRX) - Defense World
DURECT faces Nasdaq delisting over share price - Investing.com
New Strong Buy Stocks for January 9th - Yahoo Finance
Reviewing Acerus Pharmaceuticals (OTCMKTS:TRLPF) and DURECT (NASDAQ:DRRX) - Defense World
Microbial Products Market Size to Hit USD 351.42 Bn by 2034 - Precedence Research
Durect (DRRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
DURECT Corp expected to post a loss of 17 cents a shareEarnings Preview - XM
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
DURECT Corp sells ALZET product line to Lafayette - TradingPedia
Durect announces sale of Alzet line of osmotic pumps to LIC for $17.5M - TipRanks
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million - PR Newswire
DURECT Corporation (NASDAQ:DRRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: DURECT Corporation reports Q3 2024 financials - Investing.com
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ... - Yahoo Finance
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Gro - GuruFocus.com
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ... By GuruFocus - Investing.com Canada
Durect: Q3 Earnings Snapshot - Houston Chronicle
Durect Corp Q3 2024 Earnings: GAAP EPS of -$0.14 Misses Estimates, Revenue at $1.9 Million Below Expectations - GuruFocus.com
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Durect reports Q3 EPS (14c), consensus (17c) - TipRanks
DURECT Q3: $4.3M Loss, Plans Phase 3 Trial Amid Funding Needs & License Agreement End | DRRX Stock News - StockTitan
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update - StockTitan
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline News & Insights
DRRXDurect Corp Latest Stock News & Market Updates - StockTitan
DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024 - StockTitan
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Gro - GuruFocus.com
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Advances Amid ... - Yahoo Finance
Durect Corp Annual Meeting Decisions and Shareholder Votes - TipRanks
H.C. Wainwright maintains Neutral rating on Durect shares post FDA meeting - Investing.com
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis - PR Newswire
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference - PR Newswire
Durect Corp (NQ: DRRX - Financial Content
DURECT Corporation (NASDAQ:DRRX) Q2 2024 Earnings Call Transcript - Insider Monkey
DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update - PR Newswire
DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update - Yahoo Finance
Durect - The Pharma Letter
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - PR Newswire
DURECT Corporation (NASDAQ:DRRX) Q1 2024 Earnings Call Transcript - Insider Monkey
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update - PR Newswire
Durect and Sandoz signs a $293 mln development and commercialization agreement for Posimir - Reuters
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis - PR Newswire
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - PR Newswire
Durect Corp Azioni (DRRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.23%
3.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):